CRNX
Crinetics Pharmaceuticals, Inc.
33.31
USD
This page is just a preview of the data found in TrendSpider’s full version
Crinetics Pharmaceuticals, Inc. stock is up 24.8% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 5 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 09 Nov 18:15 | 15 Mar, 2024 | 22.50 | 2027 | ||
| 09 Nov 18:40 | 15 Mar, 2024 | 30.00 | 391 | ||
| 09 Nov 19:59 | 15 Mar, 2024 | 35.00 | 2352 | ||
| 09 Nov 19:59 | 15 Mar, 2024 | 22.50 | 2027 | ||
| 13 Nov 17:54 | 15 Mar, 2024 | 22.50 | 2527 | ||
| 13 Nov 17:54 | 15 Mar, 2024 | 35.00 | 2597 | ||
| 14 Nov 14:43 | 15 Mar, 2024 | 35.00 | 2427 | ||
| 30 Nov 16:51 | 15 Mar, 2024 | 35.00 | 2046 | ||
| 01 Dec 16:17 | 15 Mar, 2024 | 35.00 | 1888 | ||
| 04 Dec 19:06 | 15 Dec, 2023 | 20.00 | 101 |
Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.
